Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.60 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxycytidine Triphosphate SCHEMBL12595481 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL18785037 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL12729518 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL1615548 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL29725285 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23414482 | 0.89 | POLG (0.69) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL42135 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL703664 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL29030090 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL27673667 | 0.89 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612093-B2 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITED THERAPEUTICS CORPORATION (US) | 2009-11-03 | — | — | US | claimed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| US-20060094671-A1 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITHER VIROLOGY, LLC | 2006-05-04 | — | — | US | claimed |
| US-20050267153-A1 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | MUELLER RICHARD A | 2005-12-01 | — | — | US | claimed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | claimed |
| EP-1007058-B1 | USE OF (N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | SEARLE LLC (US) | 2005-05-18 | — | — | EP | claimed |
| US-6747149-B2 | ADMINISTERING VIRICIDES SUCH AS N-NONENYL GLUCOSAMINE, AND OPTIONALLY WITH MIXTURES OF NUCLEOSIDES, NUCLEOTIDES, IMMUNOMODULATORS OR IMMUNOSTIMULANTS FOR PROPHYLAXIS VIRAL DISEASES | G. D. SEARLE & CO. | 2004-06-08 | — | — | US | claimed |
| US-6689759-B1 | COMBINED WITH NUCLEOSIDE AND/OR NUCLEOTIDE ANTIVIRAL AGENTS AND IMMUNOSTIMULANTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2003-05-29 | — | — | US | claimed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | claimed |
| EP-1261339-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | Pharmacia Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| JP-2002502875-A | — | — | 2002-01-29 | — | — | JP | claimed |
| WO-2001060366-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | PHARMACIA CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | claimed |
| EP-1007058-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. Searle & Co. (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | claimed |
| WO-1998035685-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE AND CO. (US) | 1998-08-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094671-A1 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | HAVCR2, DERA, GALE | POLG 823/4885POLB 1646/4885P2RY2 2083/4885 |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | POLG 2016/4885POLB 1287/4885P2RY2 1702/4885 |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | HAVCR2, DERA, GALE | POLG 827/4885POLB 1427/4885P2RY2 2334/4885 |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | POLG 949/4885POLB 1716/4885P2RY2 2692/4885 |
| US-20050267153-A1 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | POLG 949/4885POLB 1716/4885P2RY2 2692/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | POLG 1353/4885POLB 1995/4885P2RY2 1650/4885 |
| US-20030220299-A1 | Especially treating hepatitis B and hepatitis C; may be used alone, or in combination with another antiviral agent such as nucleosides, nucleotides, immunomodulators, and/or immunostimulants | IMPDH1, HAVCR2, IMPDH2 | POLG 890/4885POLB 626/4885P2RY2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.